Both Enanta and Shionogi are looking to enter a market already served by RSV vaccines that can prevent infection and, in doing so, reduce the number of people who may need an antiviral.

Two RSV vaccines were approved for use in Australia last year by the Therapeutic Goods Administration. The Australian Government is funding Pfizer’s Abrysvo for pregnant women and, in an unusual ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.